Patient guides
Clear answers, no marketing spin
Researched, written and verified by the LicensedPsychedelics editorial team. Every guide is dated, sourced to primary documents, and updated when the underlying rules change. How we verify.
Demi Engemann's Ketamine Protocol on Secret Lives of Mormon Wives, Explained
Demi Engemann's on-screen ketamine therapy storyline on Hulu's Secret Lives of Mormon Wives shows a clinical depression treatment under medical supervision - not recreational use. Here is what the protocol on screen most likely is, what it would actually cost, and where comparable treatment is available legally in the US.
Secret Lives of Mormon Wives: Every Ketamine Reference, Recapped
Episode-by-episode breakdown of every ketamine therapy reference in Hulu's Secret Lives of Mormon Wives season 2. Where Demi Engemann is treated, what is shown clinically, and which scenes track with real ketamine treatment versus dramatised edits.
Reality TV vs. Reality: How Mormon Wives Edits Around Real Ketamine Therapy
Hulu's Secret Lives of Mormon Wives shows ketamine therapy compressed into highlight reels. Real clinical ketamine treatment looks different in five specific ways - here is the reality check.
The Ketamine Therapy Storyline on Secret Lives of Mormon Wives, Explained
Demi Engemann's ketamine treatment plotline on Hulu's Secret Lives of Mormon Wives season 2 sent searches for 'ketamine therapy mormon wives' up 1,600% year-over-year. Here is what is actually being shown, what is medically accurate, and where US patients access the same treatment legally.
Trump signs executive order fast-tracking psychedelic therapy: what it actually does
On April 18, 2026, President Trump signed an executive order directing the FDA to issue Priority Vouchers for psychedelic drugs, opening Right to Try access to ibogaine, and routing $50M through ARPA-H. Podcast host Joe Rogan, RFK Jr., Dr. Oz and Navy SEAL Marcus Luttrell attended. Here is a plain-English breakdown of every moving part.
Is ibogaine legal in the United States? (Updated for the 2026 executive order)
Ibogaine is Schedule I in the US, but the April 2026 executive order opens a Right to Try pathway for eligible patients. Here is what is legal today, what changes in 60 days, and where US patients actually access treatment right now.
The Right to Try Act and psychedelics: how patient access actually works in 2026
The 2026 executive order directs FDA and DEA to create a Right to Try pathway for investigational psychedelics. Here is how the law works, who qualifies, what drug sponsors have to do, and the realistic timeline for patients.
Ibogaine for veterans with PTSD: what the VA trials cover and how the 2026 order changes access
The Department of Veterans Affairs is running at least five psychedelic trials across NY, CA and OR. Here is what ibogaine research for PTSD actually shows, which VA trials are open, and how the April 2026 executive order affects veteran access.
MDMA-assisted therapy for PTSD: where it stands after the 2024 FDA rejection
Lykos Therapeutics' MDMA application was declined by the FDA in August 2024. After the April 2026 executive order, the resubmission is now eligible for a Priority Voucher. Here is what actually changed and the realistic path to approval.
Ketamine therapy cost in 2026: what you actually pay out of pocket
Ketamine clinic pricing ranges from $150 oral lozenges at home to $950 per Spravato session. Here is what each route costs, what insurance actually covers, and how to use HSA/FSA to cut the real number.
Your first ketamine infusion: what to expect, start to finish
A practical walkthrough of a first IV ketamine session for depression. What happens in the hour before, during the 40-minute infusion, in recovery, and in the days after.
Microdosing psilocybin: what the science actually says in 2026
Microdosing is popular, legally risky in most states, and the clinical evidence is weaker than the social-media confidence would suggest. Here is what the controlled trials have found, what they have not, and what to consider if you are thinking about it.
Psychedelic therapy while on antidepressants: what to taper, what not to
SSRIs, MAOIs and lithium interact with psychedelics in very different ways. Some need to be tapered weeks in advance; some must not be stopped at all. A practical guide for patients and prescribers.
Oral vs IV vs IM ketamine: the real differences
Oral lozenges, intranasal, intramuscular injection and intravenous infusion all deliver ketamine - but the experience, the onset, the clinical evidence and the price are not the same. A practical comparison.
Oregon vs Colorado psilocybin: which program is right for you
Both states run licensed adult-use psilocybin programs. They look similar on paper but differ significantly in cost, session format, facilitator training, and what happens if something goes wrong.
Which insurance plans actually cover Spravato in 2026
A plan-by-plan breakdown of Spravato (esketamine) coverage across Medicare, Medicaid, BCBS, Aetna, Cigna, United, Kaiser and Tricare - with the step-therapy hoops, prior-auth codes, and what you will actually pay out of pocket.
Treatment-resistant depression: what actually counts, and why it matters for your insurance
Every Spravato and most ketamine coverage policies are gated on 'treatment-resistant depression.' Here is what that phrase formally means, how to document it, and how to talk to your prescriber to avoid an accidental denial.
Seven questions to vet any ketamine clinic before your first session
Ketamine clinic quality varies enormously. These are the seven questions that separate a safe, integrative practice from an infusion mill - and the red flags that should make you walk away.